ClinicalTrials.gg
CompletedNCT01359462Updated May 24, 2011

Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis

A Phase 1 interventional study of tolvaptan in Hepatic Cirrhosis and Ascites, sponsored by Otsuka Beijing Research Institute. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2011-05-24.

Sponsored by Otsuka Beijing Research Institute (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
11
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.

Enrollment
121st of 127
11 · median 120
Started
2009
with 4 others
Phase 1
11 of 214
2 open now
Registered
6th of 214
by date

Among the 214 studies in Liver Cirrhosis with a site in China, this one is the 121st largest by enrollment of the 127 interventional ones that give a count, is one of 5 that started in 2009, is one of 11 in phase 1, and was the 6th registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

65 of the 214 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

For hepatic cirrhosis subjects with ascites or lower extremities, to study Pharmacokinetics, pharmacology, and safety of the drug under fasting condition.

Read the detailed description

This study is to evaluate the multiple-dose pharmacokinetics, pharmacological actions and safety of Tolvaptan tablets administered orally (15 mg daily) for consecutively 7 days in Chinese adult patients with confirmed Child-Pugh Class B(score 7-9) hepatocirrhosis (accompanied by ascites).

Trial Design:

  1. Open, single-center, multi-dose pharmacokinetics study
  2. Study population:

    Chinese adult patients with confirmed Child-Pugh Class B (score 7-9) hepatocirrhosis (accompanied by ascites)

  3. Dosage and mode of administration of investigational product:

    Oral administration of 1 tablet (15mg) once daily, for consecutive 7 days starting from day 1 of treatment.

  4. Study duration:

Screening: 14 days in maximum; Treatment(s): 7 days; Observation: 1 day

03

Conditions studied

  • Hepatic Cirrhosis
  • Ascites

Keywords

  • hepatic cirrhosis patients with ascites
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Hepatic Cirrhosis with ascites or lower extremities edema
  2. Hospitalized patients
  3. 18 years old\~75 years old
  4. Inform Consent Form Signed

Exclusion criteria

Exclusion Criteria:

  1. Patients with any of the following diseases, complications or symptoms:

    • Hepatic encephalopathy (coma degree classification note 1 Grade 2 or above);
    • Malignant ascites;
    • Spontaneous bacterial peritonitis;
    • Likely to have gastrointestinal bleeding during the study period;
    • Heart failure ( Note 2 Class Ⅲ andⅣ);
    • Anuria (daily urine output below 100mL);
    • Dysuria induced by urinary tract stenosis, calculus, or tumor.
  2. Patients with any of the following history:

    • With gastrointestinal bleeding within 10 days prior to screening;
    • With cerebrovascular accident within 1 month prior to screening;
    • With gout attack within 1 month prior to screening;
    • With allergy or atopy to benzodiazepine drugs (benazepril hydrochloride, etc.).
  3. Patients whose systolic blood pressure is below 90mmHg during screening;
  4. Patients with abnormal values in the following lab examination indicators:

    Serum creatinine higher than 2.5 times the , serum Na+>145mmol/L(or higher than the upper limit of normal range), serum K+> 5.5 mmol/L, uric acid>476µmol/L, score>10

  5. Patients ineligible for oral medication
  6. Patients in pregnancy or lactation; female of not taking measures;
  7. Patients having taken blood products including albumin products within 4 days prior to application of product;
  8. Patients having participated in clinical trials of other drugs within 1 month prior to screening;
  9. Patients used to participate in clinical trials of Tolvaptan and take the said drug;
  10. Patients determined by the investigator as illegible for the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
11 participants (actual)

Study arms

  • Experimental
    Tolvaptan 15mg tablet

    Drug: tolvaptan

Interventions

  • Drug: tolvaptan tablet, 15mg, Qd, for 7 days.

    Also known as: SAMSCA

06

What researchers measure

Primary outcomes

  1. Serum concentration of tolvaptan and its metabolites DM-4103 and DM-4107

    Time frame: blood sample will be collected at predose, 2,4,6,8,12,24 hour of first drug administration and predose of sixth drug administration and predose,2,4,6,8,12,24 hour of seventh drug administration

Secondary outcomes

  1. pharmacological parameter:Serum concentration of sodium and potassium

    Time frame: Blood sample will be collected at predose on day1;12,24hour of first dosing;before breakfast on day3 to day6;predose and 12,24hour of seventh dosing

  2. pharmacological parameter:24-hr urine

    Time frame: From day-1 to day 8

07

Study locations

1 site
  • Renji Hospital, Shanghai Jiao Tong University School of Medicine
    Shanghai, Shanghai 200001, China
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2009, a primary completion of Nov 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 5, 2010
First posted
May 24, 2011
Start
Apr 2009
Primary completionActual
Nov 2009
CompletionActual
Jan 2010
Last update
May 24, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01359462
First posted
May 24, 2011
Start date
Apr 2009
Primary completion
Nov 2009
Completion
Jan 2010
Last update
May 24, 2011

Study contacts

Minde Zeng
principal investigator · RenJi Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion